Manhattan Eye, Ear & Throat Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Phase 2

Completed

Conditions: Macular Degeneration

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Registration Number: NCT00211458

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

Phase 2

Completed

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Drug: ketoconazole

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 5

Registration Number: NCT00211393

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Phase 2

Completed

Conditions: Pseudovitellium Detachment
Eye Diseases

Interventions: Drug: Anecortave Acetate Sterile Suspension (15 mg)

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 4

Registration Number: NCT00211432

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Phase 1

Completed

Conditions: Maculopathy, Age-Related

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-24

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Registration Number: NCT00211419

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

Phase 2

Completed

Conditions: Coat's Disease

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-24

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 4

Registration Number: NCT00211315

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Phase 2

Completed

Conditions: Chronic Central Serous Chorioretinopathy

First Posted Date: 2005-09-21

Last Posted Date: 2007-09-28

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 11

Registration Number: NCT00211445

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Phase 2

Completed

Conditions: Age-Related Macular Degeneration

First Posted Date: 2005-09-01

Last Posted Date: 2007-07-12

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 106

Registration Number: NCT00140803

Locations: 🇨🇦
Vh/UBC Eye Care Centre, Vancouver, British Columbia, Canada
🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy